Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S5
Elucidating Binding Selectivity in Cyclin-Dependent Kinases 4, 6, and 9: Development of Highly Potent and Selective CDK4/9 Inhibitors.
Jiang C et al.
Journal of Medicinal Chemistry, 2025
CDKL3 is a targetable regulator of cell cycle progression in cancers.
Zhang H et al.
The Journal of Clinical Investigation, 2024
JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21.
Colleoni B et al.
Oncogene, 2017
PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
Yang H et al.
Oncotarget, 2016
CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
Bisteau X et al.
Plos Genetics, 2013
Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation.
Bockstaele L et al.
Molecular and Cellular Biology, 2009
The cyclin D1-dependent kinase associates with the pre-replication complex and modulates RB.MCM7 binding.
Gladden AB et al.
The Journal of Biological Chemistry, 2003
A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase.
Diehl JA et al.
Molecular and Cellular Biology, 1997
Identification of CDK4 sequences involved in cyclin D1 and p16 binding.
Coleman KG et al.
The Journal of Biological Chemistry, 1997
Select a paper to view details